Korro Bio, Inc. (NASDAQ: KRRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $115.00 price target on the stock.
Korro to Participate in Upcoming Investor Conferences
Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency
Korro to Present at the Jefferies London Healthcare Conference
Korro Bio, Inc. (NASDAQ: KRRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $115.00 price target on the stock.